Vaccine enthusiasm backs off
Published 13-NOV-2020 09:51 A.M.
|
2 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Equities moved lower in the latter half of the week.
According to Chris Beauchamp, Chief Market Analyst at IG, this was due to “the vaccine bounce” fading across markets.
eToro analyst Adam Vettese noticed the same thing.
“European markets were in the red, coming off their highs as infection rates continue to rise and the realisation that a vaccine is not an overnight fix dawns on investors,” Vettese said
“Despite breakthrough news from Pfizer’s vaccine trial this week, there is yet to be approval and the logistics of transporting a vaccine that must be kept at sub zero temperatures is beset with issues.”
Beauchamp noted the slow down “As enthusiasm about a vaccine begins to fade the FTSE 100 has lost ground, with a slowdown in the excited buying of hard-hit value names in sectors like travel, airlines, banks and others.
“In Europe it is a similar story, but overall, it feels like a pause rather than the beginning of a reversal.
As for the general market performance, Beauchamp noted the mixed performances.
“UK GDP data showed a strong rebound for Q3, although slightly below estimates, and any positive feelings created by the report were muted thanks to the evident slowdown in September from the euphoric performance in July and August.
“It was another mixed bag of corporate data in the UK, as B&M said that it would issue a special dividend following strong performance, while those outside of the discount bin-end of the market continue to struggle.
“WHSmith’s winning bet on international travel, such a sure thing until this year, has come unstuck, with sales in this division dropping more sharply than the old-fashioned high-street arm.
“US futures are also weaker, as the ‘rotation’ of the last few days gives way to a more ‘normal’ pattern as investors flow back towards oversold tech stocks.
“Political developments, or lack thereof, continue to have little impact, with the lack of any White House pronouncements helping to calm market nerves about the US political outlook.”
Tickers
- Dow: -0.08%
- S&P 500: -1.00%
- NASDAQ: -0.65%
- FTSE 100: -0.68%
- DAX: -1.24%
- CAC40: -1.52%
- Asia Dow: -0.19%
- Nikkei 225: +0.68%
- Hang Seng: -0.22%
- ASX XAO (All Ordinaries): -0.48%
- ASX 200 (XJO): -0.49%
- AUD: 0.72
General Information Only
This material has been prepared by StocksDigital. StocksDigital is an authorised representative (CAR 000433913) of 62 Consulting Pty Limited (ABN 88 664 809 303) (AFSL 548573).
This material is general advice only and is not an offer for the purchase or sale of any financial product or service. The material is not intended to provide you with personal financial or tax advice and does not take into account your personal objectives, financial situation or needs. Although we believe that the material is correct, no warranty of accuracy, reliability or completeness is given, except for liability under statute which cannot be excluded. Please note that past performance may not be indicative of future performance and that no guarantee of performance, the return of capital or a particular rate of return is given by 62C, StocksDigital, any of their related body corporates or any other person. To the maximum extent possible, 62C, StocksDigital, their related body corporates or any other person do not accept any liability for any statement in this material.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.